Histogen announces US patent covering CTS-2090 for inflammatory diseases

Histogen announced that the US Patent and Trademark Office or USPTO, has issued US Patent No. 11,579,703 titled "Caspase Inhibitors and Methods of Use Thereof." We believe this key patent provides broad coverage for Histogen’s portfolio of highly selective and orally active anti-inflammatory caspase inhibitors, including CTS-2090. This patent includes information that CTS-2090 has demonstrated potent oral activity in a well characterized model of ulcerative colitis. Importantly, CTS-2090 provided statistically significant protection against inflammation-driven damage to the lining of the GI tract and also protected against loss of body weight. While CTS-2090 is a potent inflammatory, it had no effect in well-accepted cellular and in vivo models of apoptosis, confirming its high selectivity as an anti-inflammatory caspase inhibitor. "We are pleased that this important patent has issued. It builds upon Histogen’s growing proprietary caspase inhibitor portfolio that includes the US patent No. 11,447,497 issued in September of 2022. This previously issued patent discloses a broad class of novel pan-caspase inhibitors with unique chemical properties," stated Alfred Spada, EVP and Chief Scientific Officer of Histogen. "In addition to these two important patents to support our expanding pipeline, we are also evaluating the potential use of our clinical stage pan-caspase inhibitor, emricasan, in acute bacterial skin infections, including those related to methicillin resistant staph aureus or MRSA."